Lv41
410 积分 2023-06-05 加入
OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
13天前
已完结
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
13天前
已完结
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
18天前
已完结
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
18天前
已完结
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study
24天前
已完结
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
24天前
已完结
Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer
24天前
已完结
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview
24天前
已完结
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
25天前
已完结
Late Recurrence of Completely Resected Stage I-IIIA Lung Adenocarcinoma
26天前
已完结
皖公网安备34019202002308
